Blends Spółka z Ograniczoną Odpowiedzialnością (KRS 0000729537, NIP 9522180394) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. Blends operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since April 27, 2018. Blends's most recently reported net revenue was 0 PLN for 2018.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Blends
Identity
- Name
- Blends Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- April 27, 2018
- Registry status as of
- November 21, 2025
- Latest entry
- November 5, 2021
- Founding act
- 28.03.2018 R., NOTARIUSZ KAROLINA KOWALIK, KANCELARIA NOTARIALNA W WARSZAWIE, REP. A NR 2208/2018.
Articles of association history (5)
- March 28, 2018: 28.03.2018 R., NOTARIUSZ KAROLINA KOWALIK, KANCELARIA NOTARIALNA W WARSZAWIE, REP. A NR 2208/2018.
- January 17, 2019: 17.01.2019 R., REP. A NR 166/2019, NOTARIUSZ WALDEMAR ADAMUS, KANCELARIA NOTARIALNA W WARSZAWIE, ZMIANA § 5 UST.1 UMOWY SPÓŁKI OBJĘTA UCHWAŁĄ NR 1 NADZWYCZAJNEGO ZGROMADZENIA WSPÓLNIKÓW ORAZ PRZYJĘCIE TEKSTU JEDNOLITEGO UMOWY SPÓŁKI OBJĘTEGO UCHWAŁĄ NR 2 NADZWYCZAJNEGO ZGROMADZENIA WSPÓLNIKÓW
- January 17, 2019: 17.01.2019 R. - WALDEMAR ADAMUS - NOTARIUSZ W WARSZAWIE, REP. A NR 166/2019 - ZMIENIONO § 5 UST. 1 (UCHWAŁA NR 3), PRZYJĘTO TEKST JEDNOLITY (UCHWAŁA NR 4).
- June 18, 2019: 18.06.2019 R., REP. A NR 1881/2019, NOTARIUSZ WALDEMAR ADAMUS, KANCELARIA NOTARIALNA W WARSZAWIE, ZMIENA §5 UST. 1 ORAZ PRZYJĘCIE TEKSTU JEDNOLITEGO; 23.07.2019 R., REP. A NR 2263/2019, NOTARIUSZ WALDEMAR ADAMUS, KANCELARIA NOTARIALNA W WARSZAWIE, ZMIANA §5 UST. 1; 25.07.2019 R., REP. A NR 2295/2019, NOTARIUSZ WALDEMAR ADAMUS, KANCELARIA NOTARIALNA W WATSZAWIE, ZMIANA §5 UST. 1.
- August 4, 2021: 8.04.2021, REP. A NR 11108/2021, NOTARIUSZ KAROLINA KOWALIK, KANCELARIA NOTARIALNA W WARSZAWIE, ZMIANA PAR. 5 UST. 1 ORAZ PRZYJĘCIE TEKSTU JEDNOLITEGO; 11.05.2021, REP. A NR 16563/2021, NOTARIUSZ KAROLINA KOWALIK, KANCELARIA NOTARIALNA W WARSZAWIE, ZMIANA PAR. 5 UST. 1 I PRZYJĘCIE TEKSTU JEDONLITEGO
Activities
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. ZASADOWA, 12B, 04-875, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.2298, 21.0117approx.
Risk and payment profile - Blends
Credibility rating
39.2 / 100
Poor credibility
Insolvency risk
Low
Elevated threat
Closure risk
28
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
2
2/8 yrs
Board changes
1
1/8 yrs
PKD changes
0
0/8 yrs
Name changes
0
0/8 yrs
Data from 8 years of registry activity.
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Blends
Founded
April 27, 2018
8 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
10.2 K PLN
141 shares total
Shareholders
3
shareholders
Board
3 people
Sup. board: 4
Filed years
1 year
2018 · profitable: 0/1
Registry entries
10
latest: November 5, 2021
Risk signals
Revenue
0 PLN
2018
Net profit
-60.7 K PLN
2018
Assets
57.0 K PLN
2018
Equity
N/A
2018
EBITDA
N/A
2018
no depreciation data
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Blends.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
